Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0MTCCV
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Telisotuzumab-CPT2
|
|||||
| Synonyms |
Telisotuzumab-CPT2
Click to Show/Hide
|
|||||
| Organization |
XADCERA BIOPHARMACEUTICAL (SUZHOU) CO., LTD.
|
|||||
| Drug Status |
Investigative
|
|||||
| Antibody Name |
undisclosed
|
|||||
| Antigen Name |
Trophoblast glycoprotein (TPBG)
|
Antigen Info | ||||
| Payload Name |
CPT2
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase I (TOP1)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Patient-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
79.80%
|
|||
| Method Description |
B-NDG mice were engrafted in the right flank with pancreatic cancer patient-derivedtumor tissue fragments (2 mm x 2 mm x 2 mm). The immunofluorescence staining results showed that TPGB-positive cells and MET-positive cells in the pancreatic tumor fragments were 58.86% and 24.08%, respectively. When the tumors in the mice reached a volume of about 150-200 mm3, the mice were randomly placed into different groups based on the tumor volume. Themice were then injected with 6mg/kg ADC's by i.v, QW, administration. Determined tumor volume after the experiment, measured at day 25.
Click to Show/Hide
|
||||
| In Vivo Model | Patient-derived Xenograft B-NDG mice Model | ||||
